ROR1-话题@MedSci

#ROR1#

1篇内容 | 1618人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2247026, encodeId=5d7d224e02604, content=<a href='/topic/show?id=34b515624f9' target=_blank style='color:#2F92EE;'>#ROR1#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a>, objectTitle=ROR1靶向ADC的研究进展, objectType=article, longId=783646, objectId=fcfde83646f5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=fcfde83646f5, replyNumber=0, likeNumber=28, createdTime=2025-01-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=fcfde83646f5, moduleTitle=ROR1靶向ADC的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcfde83646f5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2242318, encodeId=730b22423189e, content=<a href='/topic/show?id=34b515624f9' target=_blank style='color:#2F92EE;'>#ROR1#</a> <a href='/topic/show?id=567650039e9' target=_blank style='color:#2F92EE;'>#弥漫大B细胞淋巴瘤#</a> <a href='/topic/show?id=f7561223162e' target=_blank style='color:#2F92EE;'>#Zilovertamab vedotin#</a>, objectTitle=100%CR! 惊为天人! ROR1靶点的ADC——zilovertamab vedotin治疗弥漫大B细胞淋巴瘤, objectType=article, longId=855293, objectId=6225855293a9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241101/789d870b61c9429bb2ffc79cd9da6a61-wwW9lkL6XFqp.jpg, objectUrl=/article/show_article.do?id=6225855293a9, replyNumber=0, likeNumber=30, createdTime=2024-12-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=6225855293a9, moduleTitle=100%CR! 惊为天人! ROR1靶点的ADC——zilovertamab vedotin治疗弥漫大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6225855293a9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=896233, encodeId=374789623380, content=<a href='/topic/show?id=34b515624f9' target=_blank style='color:#2F92EE;'>#ROR1#</a>为<a href='/topic/show?id=07a69996557' target=_blank style='color:#2F92EE;'>#靶点#</a>, 新靶点都是有潜力的！, objectTitle=基石药业引进靶向ROR1的抗体偶联药物LCB71，超3.6亿美元！, objectType=article, longId=202793, objectId=71ca202e93e4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201009/fb30d751a22647eba5a43a85474d6c9a.jpg, objectUrl=/article/show_article.do?id=71ca202e93e4, replyNumber=0, likeNumber=0, createdTime=2020-11-02, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71ca202e93e4, moduleTitle=基石药业引进靶向ROR1的抗体偶联药物LCB71，超3.6亿美元！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71ca202e93e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ROR1

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#ROR1# #抗体偶联药物#

ROR1靶向ADC的研究进展

2025-01-08发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#ROR1# #弥漫大B细胞淋巴瘤# #Zilovertamab vedotin#

100%CR! 惊为天人! ROR1靶点的ADC——zilovertamab vedotin治疗弥漫大B细胞淋巴瘤

2024-12-14发表于威斯康星

lovetcm (审核中...)

前往app查看评论内容

#ROR1#为#靶点#, 新靶点都是有潜力的！

基石药业引进靶向ROR1的抗体偶联药物LCB71，超3.6亿美元！

2020-11-02

科室
- - 订阅+
  - 更多科室
工具
服务